Question 1

Does Rhode Island Medicaid currently cover Wegovy or Zepbound for weight loss in 2026?

Accepted Answer

Yes — as of May 15, 2026, Rhode Island Medicaid is one of only 13 states per KFF's January 2026 tracker that currently covers GLP-1 receptor agonists for chronic weight management under Medicaid fee-for-service. Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Contrave (naltrexone/bupropion) are all CURRENTLY COVERED with prior authorization under the EOHHS PDL effective January 13, 2026, and via Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC) Medicaid formularies. However, Governor Daniel McKee's FY2027 Executive Budget (Item 028, EOHHS Rank #2, introduced January 15, 2026) proposes ending this coverage effective October 1, 2026 with NO grandfathering or exemptions for existing patients. The Rhode Island General Assembly will rule on the proposal by June 2026. Rhode Island beneficiaries currently on a GLP-1 for weight loss should engage with their prescriber NOW about contingency planning, including documentation of any qualifying cardiovascular, sleep apnea, or T2D indication that may preserve coverage post-sunset.

Question 2

What is Governor McKee's FY2027 Medicaid GLP-1 sunset proposal?

Accepted Answer

Governor Daniel McKee's FY2027 Executive Budget — introduced January 15, 2026 — includes Item 028 (EOHHS Rank #2) proposing to strike GLP-1 weight-loss drugs from the Rhode Island Medicaid Preferred Drug List. Effective date per the budget submission: 'as early as July 1, 2026, but would more likely happen by October 2026 or January 2027' — with Rhode Island Current reporting 'Coverage of the drugs for weight loss would end on Oct. 1 under McKee's plan.' Projected savings: $6.3 million state general revenue, $20.3 million all-funds (federal + state combined). Mechanism per EOHHS: 'mostly an administrative change to contracts and rates' — the drugs would be 'struck from the preferred drug list.' Scope: 'would only affect prescriptions for weight loss' (T2D coverage continues); 'no grandfathering or exemptions for existing patients.' Cost driver per the budget: GLP-1 weight-loss PMPM payments to managed care plans 'roughly quadrupled' between SFY24 start and SFY25 end, with projected additional growth of approximately 130 percent (low estimate) to nearly 200 percent (high estimate) by end of FY27 Q2.

Question 3

How many Rhode Islanders use Medicaid-paid GLP-1s for weight loss?

Accepted Answer

Per Rhode Island Current's reporting of the EOHHS FY2027 budget submission, Rhode Island Medicaid paid for 24,971 GLP-1 weight-loss prescriptions in State Fiscal Year 2025 (July 1, 2024 — June 30, 2025). The number of unique beneficiaries is not publicly broken out but, assuming average refill cadence, represents several thousand unique patients who would face therapy discontinuation if the FY27 sunset takes effect October 1, 2026 without grandfathering. Equity context per RI Current citing CDC and EOHHS data: 38.5% of Black Rhode Island residents have obesity; 33.9% of Hispanic residents; 29.5% of white residents; 44.6% of adults in households earning under $15,000. Total Rhode Island Medicaid + CHIP enrollment is approximately 303,351 (September 2025) to 303,480 (October 2025) per healthinsurance.org citing KFF/CMS, with 76,455 ACA expansion enrollees as of June 2025. List price context per the budget submission: Wegovy and Zepbound run '$12,000 annually to roughly $16,000 annually as of March 2025' at WAC.

Question 4

When will the Rhode Island General Assembly decide on the GLP-1 Medicaid sunset?

Accepted Answer

Rhode Island Governor's executive budget proposals are not self-executing — they must pass the General Assembly as part of the enacted FY2027 budget. Per Rhode Island Current: 'McKee's proposal will undergo months of legislative questioning, editing and restructuring before the General Assembly's final version emerges sometime in June.' The House Finance Committee will hold hearings on the EOHHS budget items first, then the Senate Finance Committee. Final enacted budget typically passes by mid-to-late June for the fiscal year beginning July 1. The General Assembly can: (a) accept the McKee proposal as drafted (full sunset October 1, 2026); (b) accept with modifications (e.g., delayed effective date, grandfathering existing patients, indication-based carve-outs for CV/OSA/MASH); (c) reject and continue current coverage with appropriations to absorb the $20.3M cost. Rhode Island General Assembly tracker: rilegislature.gov. The Boston Globe published a November 3, 2025 commentary opposing the cut: 'GLP-1s are a game-changer for R.I.’s obesity crisis. Limiting access to these weight-loss medications is not the answer.'

Question 5

If RI Medicaid drops GLP-1 weight-loss coverage, will FDA cardiovascular Wegovy, Zepbound OSA, or Wegovy MASH still be covered?

Accepted Answer

UNVERIFIED — this is the most consequential ambiguity in the McKee FY27 proposal. The published budget item describes ending coverage of GLP-1s 'for weight loss' but does NOT publicly specify whether FDA-label-restricted indications (Wegovy for major adverse cardiovascular event risk reduction per the SELECT trial, Zepbound for moderate-to-severe obstructive sleep apnea per SURMOUNT-OSA, Wegovy for MASH per the ESSENCE trial, Wegovy pediatric ≥12 yrs per STEP TEENS) would be carved back in or eliminated together with the weight-loss indication. Becker's Payer Issues reported that EOHHS 'has commented that the weight loss policy and prior authorization criteria needs to be revisited due to the updated indication for GLP-1 agonists in patients with cardiovascular disease,' suggesting the carve-out framing is under active discussion but no public document confirms intent. This makes Rhode Island the first state in the 40-state series whose post-sunset indication-specific carve-out policy is unsettled. PRACTICAL READER ACTION: Rhode Island beneficiaries who have established cardiovascular disease (prior MI, stroke, symptomatic PAD), moderate-to-severe OSA (AHI ≥ 15 with CPAP failure/intolerance), biopsy-proven MASH F2-F3 fibrosis, or T2D should ensure these diagnoses are documented in the medical record AND on the PA before October 1, 2026 — because if the General Assembly preserves only indication-restricted carve-outs after sunset, prior documentation will be the gating factor for continued access.

Question 6

Does RI Medicaid still cover Ozempic and Mounjaro for type 2 diabetes after the sunset?

Accepted Answer

Yes. The McKee FY2027 sunset proposal is explicitly scoped to weight-loss-indicated GLP-1 prescriptions only. T2D-indicated GLP-1 receptor agonists — Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), Victoza (liraglutide), Rybelsus (oral semaglutide), and Bydureon BCise (exenatide ER) — continue to be covered under the existing RI Medicaid GLP-1 PA criteria for type 2 diabetes. The historical RI Medicaid PA framework requires 'history of either metformin or TZD therapy in the past 90 days' as the prerequisite for both the GLP-1 receptor agonist class and the DPP-IV inhibitor class. The specific 2026 PA criteria — A1c thresholds, step therapy sequencing, quantity limits, preferred-vs-non-preferred status by brand — should be verified directly from the EOHHS PDL effective January 13, 2026 (URL: eohhs.ri.gov/sites/g/files/xkgbur226/files/2026-01/PDL%2001.13.2026.pdf) and the NHPRI Medicaid GLP-1 Agonists / GIP-GLP-1 Agonists PA criteria PDF effective March 17, 2026.

Question 7

What is the current PA pathway for Wegovy, Zepbound, Saxenda, and Contrave under RI Medicaid?

Accepted Answer

Until the FY2027 sunset takes effect, prior authorization for chronic-weight-management drugs operates through the EOHHS FFS PDL or, for MCO-enrolled beneficiaries, through Neighborhood Health Plan of Rhode Island (NHPRI) or UnitedHealthcare of New England (UHC) Medicaid PA pathways. PA Form #PA04 (Weight Management) is the EOHHS form, available at eohhs.ri.gov/providers-partners/provider-directories/pharmacy/pharmacy-prior-authorization-program. PA Call Center fax: 1-401-784-3889. The EOHHS pharmacy PA program publishes the verbatim warning: 'PA FORMS LACKING ALL REQUESTED INFORMATION WILL NOT BE REVIEWED/REQUEST WILL BE DENIED.' NHPRI publishes its 2026 Medicaid Weight Loss PA criteria (Wegovy, Zepbound, Contrave, Saxenda) at nhpri.org/wp-content/uploads/2025/12/Medicaid_Weight_Loss_Contrave_Wegovy_Zepbound_aCAS.20251021-1.pdf (effective October 21, 2025). Verbatim criteria — BMI thresholds, prerequisite lifestyle intervention duration, prerequisite drug trials, weight-loss-milestone reauthorization thresholds, ICD-10 codes, T1D + pregnancy + MTC/MEN2 exclusions, quantity limits — should be confirmed directly from that PDF (binary content blocked our automated text extraction; readers should open the PDF in a browser for verbatim language).

Question 8

How does the Rhode Island Medicaid pharmacy benefit work after the July 2025 MCO consolidation?

Accepted Answer

Effective July 1, 2025, Rhode Island consolidated its Medicaid managed care contracts from three MCOs to two: Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC). Tufts Health Plan exited managed Medicaid. Phase II of the procurement (January 1, 2026) moved fully dual-eligible beneficiaries into MCO-administered Fully Integrated Dual Eligible Special Needs Plans (FIDE-SNPs). The state Single PDL — adopted by the EOHHS Pharmacy & Therapeutics Committee — operates as the floor across both MCO formularies; MCOs may add brand-specific preferences but cannot deny coverage of PDL-preferred therapies. RI Medicaid programs by population: RIte Care (families and children); Rhody Health Partners (adults); Integrity for Duals (dual-eligibles). The EOHHS P&T Committee meets in-person; the next scheduled meeting is April 7, 2026, 7:30 AM at the RI EOHHS Virks Building in Cranston (per EOHHS pharmacy page). Total Medicaid + CHIP enrollment: approximately 303,000 (~28% of Rhode Island's population of ~1.1 million — among the highest Medicaid penetration rates by share of population in the United States).

Question 9

How do I appeal a denied RI Medicaid GLP-1 PA?

Accepted Answer

Rhode Island Medicaid fair hearings are governed by 210-RICR-10-05-2 (Appeals Process and Procedures for EOHHS Agencies and Programs). Verbatim from the regulation: 'appeals must be filed pursuant to § 2.2.1(A)(4) of this Part within thirty (30) days of the contested agency action. The 30 days begins five (5) days after the mailing date of the notice of an intended agency action.' Expedited review is available 'in circumstances when the matter in dispute cannot reasonably be resolved during the standard appeals process without jeopardizing the appellant's life, health, or ability to obtain the services required to attain, maintain, or regain maximum function.' Continuation of benefits during appeal requires filing during the 'advance notice period' (10 days beginning on the fifth day after the date on the notice of intended action). For MCO denials, federal managed-care rules separately allow beneficiaries 120 calendar days to request a fair hearing — but the MCO internal grievance/appeal must typically be exhausted before fair hearing for non-eligibility disputes (PA denials = MCO appeal first). Contacts: EOHHS Appeals Office, 3 West Road, Cranston, RI 02920; HealthSourceRI line (855) 840-4774; fax (401) 223-6317; online filing via healthyrhode.ri.gov. Legal representation: Rhode Island Legal Services (401) 274-2652 or (800) 662-5034. 'All emergency expedited hearings will be scheduled and heard telephonically' per the EOHHS Appeals Office page.

Question 10

How does Rhode Island Pattern #40 compare to Maine Pattern #39 and West Virginia Pattern #36?

Accepted Answer

Rhode Island (Pattern #40) is structurally distinct from every prior pattern in the 50-state series. Maine (Pattern #39), West Virginia (Pattern #36), Arkansas (Pattern #34), Oklahoma (Pattern #24), Utah (Pattern #37), and Nebraska (Pattern #38) are CATEGORICAL-EXCLUSION states — long-standing AOM exclusions under federal Medicaid §1927(d)(2)(A) where the policy question is 'is there a carve-back-in pathway?' Rhode Island faces the INVERSE question: 'will existing coverage survive the legislature?' RI's Medicaid GLP-1 weight-loss PMPM grew approximately 400% in 18 months (SFY24 start through SFY25 end), creating fiscal pressure that drove California, New Hampshire, Pennsylvania, and South Carolina to drop coverage. Massachusetts has a parallel sunset proposal under MassHealth, making RI + MA the next dominos. The reader-action framing is therefore inverse: instead of 'document your CV/OSA/MASH indication to access otherwise-excluded coverage' (Maine, WV, AR, OK, UT, NE pattern), RI patients should 'document any qualifying CV/OSA/MASH/T2D-comorbid indication BEFORE October 1, 2026 to preserve access in case the General Assembly enacts the sunset without grandfathering.' Mississippi (Pattern #35) — the only non-expansion southern positive-coverage state — operates yet a third pattern via SPA 23-0013 carve-back-in with explicit pediatric ages-12+ pathway and a CDC growth-chart BMI-percentile table in the PA form.

Question 11

Is Rhode Island a Medicaid expansion state?

Accepted Answer

Yes. Rhode Island expanded Medicaid under the Affordable Care Act effective January 1, 2014 — the same effective date as the federal expansion start — extending coverage to adults 19-64 at or below 138% of the federal poverty level. Total Rhode Island Medicaid + CHIP enrollment is approximately 303,351 (September 2025) per healthinsurance.org citing KFF/CMS, representing roughly 28% of Rhode Island's population of approximately 1.1 million — among the highest Medicaid-share-of-population rates in the United States. ACA expansion enrollees specifically: 76,455 as of June 2025. Rhode Island has historically been one of the most progressive states on Medicaid coverage of anti-obesity medications, having maintained AOM coverage when many state Medicaid programs declined to extend it. The McKee FY2027 sunset proposal — if enacted by the General Assembly — would represent a policy reversal of Rhode Island's prior progressive AOM stance, joining the trajectory of California, New Hampshire, Pennsylvania, and South Carolina.

Question 12

What cash-pay or compounded options are available if RI Medicaid drops GLP-1 weight-loss coverage?

Accepted Answer

If the McKee FY2027 sunset takes effect October 1, 2026 without grandfathering or indication-specific carve-outs, affected Rhode Island beneficiaries have several practical paths. (1) Manufacturer cash-pay: Novo Nordisk NovoCare Wegovy at $199-$349/month depending on dose and pen vs. oral; LillyDirect Zepbound vials at $299-$699/month; LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month self-pay. (2) Patient assistance programs: Novo Nordisk PAP for Wegovy and Lilly Cares for Zepbound, both income-tested. (3) LegitScript-approved compounded telehealth: typical market prices $99-$199/month for compounded semaglutide and $149-$249/month for compounded tirzepatide as of May 2026 — but note the FDA tirzepatide compounding-resolved status (October 2024) and semaglutide compounding-resolved status (February 2025) means new compounded prescriptions require documented patient-specific clinical need beyond shortage justification. (4) Indication-specific appeal: if the General Assembly preserves CV/OSA/MASH/T2D-comorbid indication carve-outs after sunset, beneficiaries with established CVD, moderate-to-severe OSA, biopsy-proven MASH F2-F3, or T2D should file a fresh PA citing the FDA-labeled indication rather than weight loss. (5) Employer-sponsored insurance: Rhode Island beneficiaries who transition off Medicaid (e.g., expansion population at 138% FPL who increase earnings) should investigate ESI formulary options.

Question 13

What legislative bills are pending in the Rhode Island General Assembly on GLP-1 coverage?

Accepted Answer

UNVERIFIED — as of May 15, 2026 we have not located a standalone bill in the Rhode Island General Assembly 2025 or 2026 sessions that specifically addresses GLP-1 or AOM Medicaid coverage. The policy lever is the FY2027 Executive Budget itself (Item 028, EOHHS Rank #2), which the General Assembly will review and pass with or without modification by mid-to-late June 2026. The House Finance Committee and Senate Finance Committee are the operative venues. Rhode Island General Assembly tracker: rilegislature.gov. Caseload Estimating Conference November 2025 EOHHS testimony (URL: rilegislature.gov/Special/rcc/REC202511/EOHHS%201.%20Nov%202025%20CEC%20-%20EOHHS%20Medicaid%20Testimony.pdf) contains additional fiscal detail that may surface during budget hearings — readers should pull the PDF in browser for verbatim figures (automated text extraction was blocked by the binary PDF encoding). The Boston Globe published a November 3, 2025 commentary opposing the cut, suggesting an active public-discourse arc through the 2026 legislative session.

Question 14

What should Rhode Island beneficiaries on a GLP-1 do right now?

Accepted Answer

Five practical actions before the General Assembly rules in June 2026 and the proposed October 1, 2026 sunset effective date. (1) Document indication-eligible diagnoses in your medical record: cardiovascular disease history (MI, stroke, symptomatic PAD), moderate-to-severe OSA (AHI ≥ 15 from a sleep study with documented CPAP failure or intolerance for 90+ days), biopsy-proven MASH F2-F3 fibrosis (if applicable), or T2D (if applicable). If any of these are present, ensure your PA on file is structured around the indication-restricted carve-out language, not chronic weight management — because if the General Assembly preserves indication carve-outs after sunset, the diagnosis on file will gate continued access. (2) Engage your prescriber NOW about contingency planning — including the cash-pay manufacturer options (NovoCare Wegovy, LillyDirect Zepbound, LillyDirect Foundayo) and timing of any planned dose changes that might trigger re-PA. (3) If you are at the maintenance dose threshold (e.g., Wegovy 1.7-2.4 mg, Zepbound 7.5-15 mg, Saxenda 3.0 mg) and the FY27 sunset takes effect mid-titration, request a 90-day supply at last-covered approval. (4) File for fair hearing within 30 days of any denial — and request expedited review if the matter cannot reasonably wait. (5) Contact your state senator and representative through rilegislature.gov to weigh in on the budget proposal during the House Finance Committee and Senate Finance Committee hearings. Rhode Island Legal Services (401-274-2652 or 800-662-5034) provides free representation for Medicaid appeals.

Question 15

Does RI Medicaid cover compounded semaglutide or tirzepatide?

Accepted Answer

No. Like all 39 prior states in the series, Rhode Island Medicaid does not reimburse compounded semaglutide or compounded tirzepatide under any pathway. The PDL covers specific FDA-approved branded products (Wegovy, Zepbound, Saxenda, Contrave for weight management; Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise for T2D); compounded versions fall outside the FDA-approved labeling that gates PDL coverage. Rhode Island patients who use compounded GLP-1 products pay out-of-pocket through LegitScript-approved telehealth platforms. The October 2024 FDA tirzepatide compounding-resolved declaration and February 2025 semaglutide compounding-resolved declaration mean new compounded prescriptions for these molecules now require documented patient-specific clinical need beyond the previous shortage justification. Note that if RI Medicaid drops branded GLP-1 weight-loss coverage post-sunset, the compounded option becomes the only sub-$300/month path for affected patients — but the FDA's resolved-shortage framework constrains the legality of new compounded prescriptions for unmodified molecules.

Element	Detail (verbatim where quoted)
Effective date	“Coverage of the drugs for weight loss would end on Oct. 1 under McKee’s plan.” Budget document allows flexibility: “as early as July 1, 2026, but would more likely happen by October 2026 or January 2027.” (Rhode Island Current, Jan 27, 2026)
State general revenue savings	$6.3 million
All-funds savings (federal + state)	$20.3 million
Mechanism	“Mostly an administrative change to contracts and rates” — drugs would be “struck from the preferred drug list” (EOHHS spokesperson, Ocean State Media)
Cost-growth driver	PMPM payments to managed care plans “roughly quadrupled” SFY24 start → SFY25 end. Projected FY27 Q2 growth: “approximately 130 percent (low estimate) and nearly 200 percent (high estimate).”
SFY25 prescription volume	24,971 prescriptions for GLP-1s addressing obesity (Becker’s Payer Issues, citing budget submission)
List-price context	“$12,000 annually to roughly $16,000 annually as of March 2025” (WAC for Wegovy / Zepbound at maintenance dose)
Scope	“Would only affect prescriptions for weight loss”; T2D coverage continues. “No grandfathering or exemptions for existing patients.”
Legislative path	House Finance Committee → Senate Finance Committee → enacted budget by mid-to-late June 2026 (“McKee’s proposal will undergo months of legislative questioning, editing and restructuring before the General Assembly’s final version emerges sometime in June”)
CV / OSA / MASH / pediatric carve-out language	UNVERIFIED. Budget proposal does not publicly specify whether FDA-label-restricted indications (Wegovy SELECT MACE, Zepbound SURMOUNT-OSA, Wegovy ESSENCE MASH, Wegovy STEP TEENS pediatric ≥12 yrs) would be carved back in or eliminated together with the weight-loss indication. Becker’s reports EOHHS “has commented that the weight loss policy and prior authorization criteria needs to be revisited due to the updated indication for GLP-1 agonists in patients with cardiovascular disease.”

Group	States (Patterns)	Policy question
Categorical exclusion + carve-back-in (Wegovy CV / OSA / MASH / pediatric)	ME #39, WV #36, AR #34, OK #24, UT #37, NE #38, MS #35	Is there a carve-back-in pathway? Document CV/OSA/MASH indication to ACCESS otherwise-excluded coverage.
Active-coverage stable (no public sunset proposal)	MA, CT, NY (pending in series), WI, MI	Standard PA management; coverage in place, no immediate sunset risk.
Active-coverage with imminent sunset proposal	Rhode Island Pattern #40, MA parallel proposal pending	Will existing coverage SURVIVE the legislature? Document CV/OSA/MASH/T2D-comorbid indication BEFORE Oct 1, 2026 to preserve access.
Coverage previously dropped	CA, NH, PA, SC, NC (briefly)	Coverage eliminated; cash-pay or compounded telehealth only.

Rhode Island Medicaid GLP-1 Coverage 2026: Pattern #40 — Active Coverage With Governor-Proposed October 1, 2026 Sunset (24,971 SFY25 Prescriptions, $20.3M All-Funds Savings, No Grandfathering)

Current coverage status (May 15, 2026)

What RI Medicaid covers today

The FY2027 sunset proposal — full primary-source breakdown

PA pathway — current process (pre-sunset)

FFS submission

MCO submission

Appeals and fair-hearing pathway

What Rhode Island beneficiaries should do right now

How Pattern #40 fits the 50-state series

Related coverage

Primary sources